Resources

Experts underline benefits of SMBG for all types of diabetes treatment plans.

If obesity rates just remain stable, in the next 25 years, the number of Americans living with diabetes will nearly double, increasing from 23.7 million in 2009 to 44.1 million in 2034. Over the same period, spending on diabetes will  triple, rising from $113 billion to $336 billion, even with …

Researchers at the Salk Institute for Biological Studies, La Jolla, CA,  found that, when you eat may be just as vital to your health as what you eat. Their experiments revealed that the daily waxing and waning of thousands of genes in the liver — the body’s metabolic clearinghouse — …

Researchers from the University of California, San Diego, recently offered the sharpest-yet picture of how core biochemical pathways in skeletal muscle cells and fat cells are altered in people who suffer from insulin resistance — a primary defect in Type 2 diabetes and obesity.

In adult diabetes patients with cognitive impairment, higher levels of social support for diabetes care may ameliorate the poor glycemic control often seen in these patients.

A Loyola University Health System study has found that one out of five Type 2 diabetes patients is morbidly obese — approximately 100 pounds or more overweight.

Over time, patients with Type 2 diabetes lose insulin-producing cells, a difficulty that aggravates their disease. Researchers now have identified a mechanism that triggers the problem, giving a chance to find targets for drugs to protect these crucial cells.

Despite the large number of cases of diabetes diagnosed in the United States, many Americans still lack basic knowledge about the disease. Less then 50% of those diagnosed with diabetes know that diabetes is a risk factor for heart disease, the leading cause of death in the U.S..

Many people who are overweight or obese develop insulin resistance and Type 2 diabetes at some stage in their lives. A European research team has now discovered that obese people have large amounts of the molecule CXCL5, produced by certain cells in fatty tissue.

Patients with new-onset Type 1 diabetes were modestly better able to retain beta cell function after treatment with the B-cell depleting agent rituximab (Rituxan), researchers said.